Art R. Rastinehad D.O.

Northwell Health’s System Director for Prostate Cancer at the Cancer Institute

Vice Chair of Urology at Lenox Hill Hospital

Art Rastinehad, D.O. joined the faculty at Northwell Health in January 2020.  He is the Northwell Health’s System Director for Prostate Cancer at the Cancer Institute and the Vice Chair of Urology at Lenox Hill Hospital.  He trained at the National Cancer Institute as an Interventional Urologic Oncologist and is the first urologist to be dual fellowship trained in Urologic Oncology and Interventional Radiology. He has expertise in a wide array of interventional radiological and surgical techniques, including image guided procedures, prostate artery embolization, laparoscopic and robotic surgery. 

Dr. Rastinehad’s prostate cancer team has now incorporated state-of-the-art imaging to help visualize suspicious areas in the prostate for cancer. Dr. Rastinehad has also authored and implemented clinical trials of new techniques in the diagnosis and treatment of localized prostate cancer. In 2011 at Northwell Heath, he was the principle investigator for a Phase III clinical trial using MRI/Ultrasound fusion technology to improve prostate biopsy techniques.  Using information from the prostate MRI, we can now target specific areas to better diagnose and quantify a patient’s prostate cancer. This was the first trial of this technology in the United States outside the National Institutes of Health.

This new clinical approach is helping to lay a foundation for the evaluation of a new technique, Focal Therapy, which only treats the diseased portion of the prostate.  As of May 2016, Dr Rastinehad was the first in the world to perform a gold nano-particle directed ablation using an transperineal MR US Fusion guided focal therapy system.  Dr Rastinehad and his team recently published the first series using this new technology in Proceedings of the National Academy of Science (PNAS).

For more information, please visit www.interventionalurology.com.